市場調查報告書
商品編碼
1123146
多發性硬化症的全球市場:預測(2022年~2028年)Global Multiple Sclerosis Market Research and Forecast 2022-2028 |
全球多發性硬化症的市場規模,在預測期間內預計以約2.5%的年複合成長率擴大。多發性硬化症的盛行率上升,政府的啟發活動,保險償付政策成為該市場的推動要素。
本報告提供全球多發性硬化症市場相關調查,市場概要,以及各類型,各診斷技術,各給藥模式,各類藥物,各地區的趨勢,及加入此市場的主要企業簡介等資訊。
Global Multiple Sclerosis Market Size, Share & Trends Analysis Report By Types (PPMS, PRMS, RRMS, SPMS) By Diagnostics Technologies (MRI, Evoked Potential Test, Spinal Fluid Test, and Others) By Mode of Administration (Injectable Agents, Oral Agents, and Intravenous Therapy) By Drug Class (Immunomodulators, and Immunosuppressant) Forecast, 2021-2027
The global multiple sclerosis market is anticipated to grow at a CAGR of around 2.5% during the forecast period. Multiple sclerosis is a potentially disabling disease of the brain and spinal cord. In MS communication problems between the brain and the rest of the body arises due to the attacking of immune systems on protective sheath (myelin) that covers nerve fibers. The exact mechanism of MS is not correctly understood, although several environmental, immunological, and genetic factors have been suggested in the pathogenesis of the disease. The rising prevalence of MS, awareness program by the government, and reimbursement policies are the driving factor of the MS market. According to the Multiple Sclerosis Trust, 2.5 million people in the world are estimated to have multiple sclerosis. Moreover, according to the study of McKenzie et al at the University of Dundee, the number of people with MS in the UK is growing by around 2.4% per year, due to people with MS living longer. The government program for multiple sclerosis specifically by the US government such as Emergency Assistant Program, Assistive Technology Program, and Computer Program by multiple sclerosis Focus Foundation for multiple sclerosis, played a vital role in the growth of the market.
Moreover, the shift in the preference towards oral drugs, the launch of new pipeline products, the rising need for better multiple sclerosis treatments, and rising government initiatives are expected to fulfill the market prospects during the forecast periods. The high cost of multiple sclerosis drugs and diagnostics technologies, harmful effects of the treatment and lack of awareness in the emerging economies are restraining the growth of the multiple sclerosis market. The robust range of upcoming pipeline drugs for the treatment is the opportunity of the market. The global multiple sclerosis market is hardly hit by the impact of COVID-19 due to the disruption in the supply chain and halt in the production of new drugs.
Segmental Outlook
The global multiple sclerosis market is segmented based on types, diagnostics technologies, mode of administration, and drug class. Based on types, the global multiple sclerosis is categorized into primary progressive multiple sclerosis, progressive relapsing multiple sclerosis, relapsing remitting multiple sclerosis, and secondary progressive multiple sclerosis. Among these, relapsing remitting multiple sclerosis held the major market share owing to the highest prevalence rate of RRMS globally. Based on diagnostic technologies, the market is segregated into MRI, evoked potential test, spinal fluid test, and others. Similarly, based on the mode of administration, the global market for multiple sclerosis is breakdown into injectable agents, oral agents, and intravenous therapy. Among these, the oral agents segment dominated the market in 2020, and it is further expected to maintain its dominance in the multiple sclerosis market during the forecast period. As oral agents such as dimethyl fumarate, teriflunomide, cladribine provide high satisfaction and faster relief, due to which their demand is high in multiple sclerosis treatment. Whereas according to drug class, the market is bifurcated into immunomodulators, and immunosuppressant.
Global Multiple Sclerosis Market Share by Drug Class, 2020 (%)
Global Multiple Sclerosis Market Share by Drug Class
The immunosuppressants Hold the Largest Share in Global Multiple Sclerosis Market
Among drug class, immunosuppressants dominated the market, and it is further projected to be the largest contributor in the global multiple sclerosis market during the forecast period. The rising prevalence of relapsing-remitting multiple sclerosis (RRMS) creating the demand for immunosuppressants. These drugs are highly recommended in the treatment of RRMS owing to their beneficial effects. The most commonly used immunosuppressive agents in MS are azathioprine, cyclophosphamide, methotrexate, and mitoxantrone. These agents are approved by the US FDA to be used in MS treatments. Further developments and approvals to immunosuppressants drugs are expected to propel the market growth globally during the forecast period.
Regional Outlook
Geographically, the global multiple sclerosis market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, ASEAN and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Asia-Pacific is expected to be the fastest growing in the global multiple sclerosis market during the forecast period. China, India, Malaysia are the major economies contributing highly towards the growth of the market owing to the development in the healthcare sector, and rising disposable income. Growing awareness about the diagnosis and treatment options for multiple sclerosis, and the presence of a huge patient population coupled with multiple sclerosis are also the prominent factors driving the market growth.
Global Multiple sclerosis Market Growth, By Region 2021-2027
Global Multiple sclerosis Market Growth, By Region
North America Holds the Largest Share in Global Multiple Sclerosis Market
Geographically, North America dominated the market by holding the largest share in the global multiple sclerosis market, and it is anticipated to grow at a significant CAGR during the forecast period. The market growth in the region is mainly attributed to the increasing prevalence of MS in the US region. According to The National Multiple Sclerosis Society estimates, in 2017, nearly 1 million adults (up to 913,925) were living with multiple sclerosis in the US, and this is further estimated to grow. The development in medical sectors, increasing R&D programs, are growing focus towards awareness of multiple sclerosis considered as driving factors for market growth. Besides, the availability of treatment and drugs for multiple sclerosis therapies due to the advancement in healthcare infrastructures, and government initiatives for multiple sclerosis treatment and awareness is also propelling the market growth. The presence of major market players in the region also affects the market growth positively.
Market Players Outlook
The key players in the multiple sclerosis market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market include are AbbVie Inc., Bayer AG, Merck KGaA, Mylan N.V., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., among Others. These market players are adopting several market strategies including product launch and approvals, merger and acquisition, partnership collaboration, business, and capacity expansion and others. For instance, in January 2018, Mylan has launched a generic Glatiramer Acetate injection used in the treatment of relapsing forms of multiple sclerosis (MS), in the US market.
The Report Covers
Market value data analysis of 2020 and forecast to 2027.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global multiple sclerosis market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.